Anxiolytic action of neuromedin-U and neurotransmitters involved in mice

G. Telegdy, A. Adamik

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peptide Neuromedin-U (NmU) is widely distributed in the central nervous system and the peripheral tissues. Its physiological effects include the regulation of blood pressure, heart rate, and body temperature, and the inhibition of gastric acid secretion. The action of NmU in rats is mediated by two G-protein-coupled receptors, NmU-1R and NmU-2R. NmU-2R is present mainly in the brain, and NmU-1R mainly in the periphery. Despite the great variety of the physiological action of NmU, little is known about its possible effects in different forms of behavior, such as anxiety. In the present work, NmU-23 (the rodent form of the peptide) was tested for its effect on anxiety in elevated plus maze test in mice. For detection of the possible involvement of neurotransmitters, the mice were pretreated with receptor blockers: haloperidol (a D2, dopamine receptor antagonist), propranolol (a β-adrenergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), phenoxybenzamine (a nonselective α-adrenergic receptor antagonist) or nitro-. l-arginine (a nitric oxide synthase inhibitor). The peptide and nitro-. l-arginine were administered into the lateral brain ventricle, while the receptor blockers were applied intraperitoneally.An NmU-23 dose 0.5. μg elicited anxiolytic action, whereas this action is faded away when the dose was increased. For further testing therefore 0.5. μg i.c.v. was used. Propranolol and atropine fully blocked the NmU-induced anxiolytic action, while haloperidol, phenoxybenzamine and nitro-. l-arginine were ineffective.The results suggest that β-adrenergic and cholinergic mechanisms are involved in the anxiolytic action of NmU.

Original languageEnglish
Pages (from-to)137-140
Number of pages4
JournalRegulatory Peptides
Volume186
DOIs
Publication statusPublished - Sep 10 2013

Fingerprint

Anti-Anxiety Agents
Neurotransmitter Agents
Arginine
Phenoxybenzamine
Adrenergic Antagonists
Haloperidol
Atropine
Propranolol
Peptides
Brain
neuromedin U
Anxiety
Lateral Ventricles
Gastric Acid
Blood pressure
Cholinergic Antagonists
Neurology
Muscarinic Receptors
G-Protein-Coupled Receptors
Body Temperature

Keywords

  • Anxiolytic action
  • NmU
  • Transmitters

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Anxiolytic action of neuromedin-U and neurotransmitters involved in mice. / Telegdy, G.; Adamik, A.

In: Regulatory Peptides, Vol. 186, 10.09.2013, p. 137-140.

Research output: Contribution to journalArticle

@article{7ac0d04dee644c6ca39e5d4607ba74b5,
title = "Anxiolytic action of neuromedin-U and neurotransmitters involved in mice",
abstract = "Peptide Neuromedin-U (NmU) is widely distributed in the central nervous system and the peripheral tissues. Its physiological effects include the regulation of blood pressure, heart rate, and body temperature, and the inhibition of gastric acid secretion. The action of NmU in rats is mediated by two G-protein-coupled receptors, NmU-1R and NmU-2R. NmU-2R is present mainly in the brain, and NmU-1R mainly in the periphery. Despite the great variety of the physiological action of NmU, little is known about its possible effects in different forms of behavior, such as anxiety. In the present work, NmU-23 (the rodent form of the peptide) was tested for its effect on anxiety in elevated plus maze test in mice. For detection of the possible involvement of neurotransmitters, the mice were pretreated with receptor blockers: haloperidol (a D2, dopamine receptor antagonist), propranolol (a β-adrenergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), phenoxybenzamine (a nonselective α-adrenergic receptor antagonist) or nitro-. l-arginine (a nitric oxide synthase inhibitor). The peptide and nitro-. l-arginine were administered into the lateral brain ventricle, while the receptor blockers were applied intraperitoneally.An NmU-23 dose 0.5. μg elicited anxiolytic action, whereas this action is faded away when the dose was increased. For further testing therefore 0.5. μg i.c.v. was used. Propranolol and atropine fully blocked the NmU-induced anxiolytic action, while haloperidol, phenoxybenzamine and nitro-. l-arginine were ineffective.The results suggest that β-adrenergic and cholinergic mechanisms are involved in the anxiolytic action of NmU.",
keywords = "Anxiolytic action, NmU, Transmitters",
author = "G. Telegdy and A. Adamik",
year = "2013",
month = "9",
day = "10",
doi = "10.1016/j.regpep.2013.07.008",
language = "English",
volume = "186",
pages = "137--140",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",

}

TY - JOUR

T1 - Anxiolytic action of neuromedin-U and neurotransmitters involved in mice

AU - Telegdy, G.

AU - Adamik, A.

PY - 2013/9/10

Y1 - 2013/9/10

N2 - Peptide Neuromedin-U (NmU) is widely distributed in the central nervous system and the peripheral tissues. Its physiological effects include the regulation of blood pressure, heart rate, and body temperature, and the inhibition of gastric acid secretion. The action of NmU in rats is mediated by two G-protein-coupled receptors, NmU-1R and NmU-2R. NmU-2R is present mainly in the brain, and NmU-1R mainly in the periphery. Despite the great variety of the physiological action of NmU, little is known about its possible effects in different forms of behavior, such as anxiety. In the present work, NmU-23 (the rodent form of the peptide) was tested for its effect on anxiety in elevated plus maze test in mice. For detection of the possible involvement of neurotransmitters, the mice were pretreated with receptor blockers: haloperidol (a D2, dopamine receptor antagonist), propranolol (a β-adrenergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), phenoxybenzamine (a nonselective α-adrenergic receptor antagonist) or nitro-. l-arginine (a nitric oxide synthase inhibitor). The peptide and nitro-. l-arginine were administered into the lateral brain ventricle, while the receptor blockers were applied intraperitoneally.An NmU-23 dose 0.5. μg elicited anxiolytic action, whereas this action is faded away when the dose was increased. For further testing therefore 0.5. μg i.c.v. was used. Propranolol and atropine fully blocked the NmU-induced anxiolytic action, while haloperidol, phenoxybenzamine and nitro-. l-arginine were ineffective.The results suggest that β-adrenergic and cholinergic mechanisms are involved in the anxiolytic action of NmU.

AB - Peptide Neuromedin-U (NmU) is widely distributed in the central nervous system and the peripheral tissues. Its physiological effects include the regulation of blood pressure, heart rate, and body temperature, and the inhibition of gastric acid secretion. The action of NmU in rats is mediated by two G-protein-coupled receptors, NmU-1R and NmU-2R. NmU-2R is present mainly in the brain, and NmU-1R mainly in the periphery. Despite the great variety of the physiological action of NmU, little is known about its possible effects in different forms of behavior, such as anxiety. In the present work, NmU-23 (the rodent form of the peptide) was tested for its effect on anxiety in elevated plus maze test in mice. For detection of the possible involvement of neurotransmitters, the mice were pretreated with receptor blockers: haloperidol (a D2, dopamine receptor antagonist), propranolol (a β-adrenergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), phenoxybenzamine (a nonselective α-adrenergic receptor antagonist) or nitro-. l-arginine (a nitric oxide synthase inhibitor). The peptide and nitro-. l-arginine were administered into the lateral brain ventricle, while the receptor blockers were applied intraperitoneally.An NmU-23 dose 0.5. μg elicited anxiolytic action, whereas this action is faded away when the dose was increased. For further testing therefore 0.5. μg i.c.v. was used. Propranolol and atropine fully blocked the NmU-induced anxiolytic action, while haloperidol, phenoxybenzamine and nitro-. l-arginine were ineffective.The results suggest that β-adrenergic and cholinergic mechanisms are involved in the anxiolytic action of NmU.

KW - Anxiolytic action

KW - NmU

KW - Transmitters

UR - http://www.scopus.com/inward/record.url?scp=84884396274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884396274&partnerID=8YFLogxK

U2 - 10.1016/j.regpep.2013.07.008

DO - 10.1016/j.regpep.2013.07.008

M3 - Article

C2 - 23892031

AN - SCOPUS:84884396274

VL - 186

SP - 137

EP - 140

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

ER -